Primer: Suzhou Genhouse Bio (SGHB HK) - Aug 2026
Suzhou Genhouse Bio is a clinical-stage biopharmaceutical company with a strategic focus on developing innovative small-molecule oncology...
94 Views
Suzhou Genhouse Bio (SGHB HK): Synthetic Expert Call Transcript (10 Aug 2026)
Gilead’s $80 million upfront payment for MAT2A inhibitor GH31 validates Genhouse's synthetic lethality platform but creates a critical strategic...
115 Views
IPO Databook: Suzhou Genhouse Bio (HK) - Aug 2026
Suzhou Genhouse Bio Co., Ltd., founded in May 2014, develops innovative oncology drug candidates, focusing on RAS signaling pathways and...
128 Views
Suzhou Genhouse Bio (勤浩医药) Pre-IPO: Moderate Innovation, Capped by Combination Economics
Suzhou Genhouse Bio plans to raise over USD100m through a Hong Kong listing with Huatai as the sponsor. We look at their core product GH21, their...
194 Views
Aequitas ECM Weekly (16 March 2026)- Past A/H Trends, Delton, Raajmarg, Ringpai, FS.com, Everdisplay
Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
303 Views